Bioretec

Bioretec's mission is to transform orthopedic care by merging biology and technology to create implants that facilitate the body's natural healing process and then safely absorb. Its key achievement is the 2023 FDA approval of RemeOs™, the world's first commercially available absorbable metal orthopedic implant. The company's strategy centers on scaling commercial operations in the United States, advancing its development pipeline, and launching new products to address significant unmet needs in pediatric and adult trauma, sports medicine, and elective procedures. A recent rights issue aims to strengthen its capital base to fund this growth.

Bioretec's innovation is built on two proprietary platforms: RemeOs™, the world's first commercially available absorbable magnesium alloy for high-strength applications, and Activa™, based on clinically proven self-reinforced PLGA polymer technology for reliable bioabsorbable fixation.

Bioretec competes with giant permanent implant makers (e.g., Stryker, J&J) on value and with polymer-based absorbable players (e.g., Arthrex) on technology. Its key advantage is the first-mover status with RemeOs™, the first FDA-approved absorbable metal implant, creating a temporary moat against other magnesium alloy developers.